Integrated in-silico and in-vitro analysis of lncRNA H19/miRNA-675/p53 in OSCC:
Structural characterization and molecular docking insights
#MMPMID41199286
Sekar R
; Jayaraman S
; Veeraraghavan V
; Varadarajan S
; Alagumuthu M
; Rajendran P
; Venkatesalu B
Diagn Pathol
2025[Nov]; 20
(1
): 124
PMID41199286
show ga
BACKGROUND: Long non-coding RNAs (lncRNA) H19 has drawn special attention because
of its varied role in several malignancies, including OSCC. Therefore, this study
was conducted to assess the association between H19-miR675-p53 by in-silico
analysis, quantify the expression levels of H19, miRNA-675, and target oncogene
p53 in cancerous versus normal individuals, and Correlate the Clinicopathological
findings with their expression pattern. METHODS: The secondary structure of
lncRNA H19 was predicted using the RNAfold web server (
http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi ). The FASTA sequence
of H19 was retrieved from the NCBI database ( https://www.ncbi.nlm.nih.gov/ ). We
performed molecular docking studies to analyze the interaction between miRNA-675
and p53 using the MDockPP ( https://zougrouptoolkit.missouri.edu/MDockPP/ ) web
server. Real-time PCR was used to measure the amounts of H19 and miR-675, and
Immunohistochemistry was used to analyse the pattern of p53 expression. RESULT:
The study successfully associated miR-675 from the first exon of H19 modulating
p53 via in silico analysis. It was found that H19 and miR-675 levels were higher
in OSCC patients (3.12?±?1.16) compared to healthy patients (1.0?±?0.0), and was
statistically significant (p-value?
free
free
free
